MediciNova to Begin Phase 2 Clinical Trial on MN-001 (Tipelukast) for Treatment of Moderate to Severe IPF
MediciNova Inc., a biopharmaceutical company focused on small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced the start of a Phase 2 study on its product MN-001 (tipelukast) as treatment for patients with a diagnosis of moderate to severe idiopathic pulmonary fibrosis (IPF). IPF…